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Research
Accruing evidence indicates that exposure to
environmental compounds that affect the
function of the endocrine system may
adversely impact human health. These sub-
stances deemed “endocrine disrupting com-
pounds,” or EDCs, are agents that disrupt or
enhance known regulatory functions of the
endocrine system and function through mul-
tiple mechanisms, including alteration of hor-
mone receptor function (Henley 2006;
Welshons et al. 2003). While mechanisms by
which these effects occur and the level of risk
posed to humans have yet to be fully eluci-
dated, the biological significance of EDC
exposure can be significant. In humans, a
putative link has been established between
increased abundance of estrogenic EDCs in
the environment and both rising hormone-
dependent cancer incidence and reduced
fertility (Huff et al. 1996). Thus, recent
investigations have placed particular emphasis
on delineating the consequence of estrogenic
EDC exposure on reproductive tissues.
One such agent, 4,4´-isopropylidene-2-
diphenol (bisphenol A, BPA), has been iden-
tified as a mitogen for a subset of prostate
cancers (Wetherill et al. 2002, 2005, 2006).
BPA is a nonplaner plasticizer, which is
leached in microgram quantities from poly-
carbonate plastics and epoxy resins into food
and water supplies (Welshons et al. 2003).
More than 800 million kilograms of this
compound are generated annually in the
United States, and up to 95% of adults in the
United States have detectable BPA in their
urine (Calafat et al. 2005), with adult serum
concentrations reported to range in nano-
molar concentrations [reviewed by Welshons
et al. (2006)]. BPA is known to harbor estro-
genic activity; this compound is a weak ago-
nist of both estrogen receptor alpha and beta
(ERα and ERβ, respectively) (Kuiper et al.
1997) and is capable of stimulating moderate
estrogen-independent proliferation in breast
cancer cells (Hess-Wilson et al. 2006; Olsen
et al. 2003). The ERs are members of the
steroid hormone nuclear receptor family of
transcription factors, which are activated by
speciﬁc steroid hormones and control numer-
ous molecular pathways in hormone respon-
sive tissues, including differentiation and
proliferation (Ascenzi et al. 2006; Shang and
Brown 2002). Although these reports high-
lighted a potentially influential role of BPA
on ER activity in breast cancer, recent studies
reveal BPA as an agonist for mutant androgen
receptor (AR) activity in recurrent prostate
cancer (Wetherill et al. 2002, 2005, 2006).
Prostatic adenocarcinomas are uniquely
dependent on AR activity for growth and pro-
liferation (Trapman and Brinkmann 1996). In
prostate cancer cells, androgen [testosterone or
dihydrotestosterone (DHT) binding activates
the receptor to bind DNA at androgen-respon-
sive elements (AREs), recruit co-activators, and
initiate a program of gene transcription that
induces cellular proliferation (Lee et al. 1995).
Given the reliance of prostate cancer cells on
this signal, nulliﬁcation of AR activity is the
first line of therapeutic intervention for dis-
seminated disease, as achieved through either
ligand depletion (androgen ablation strategies)
or through the use of direct AR antagonists
that prevent formation of active AR transcrip-
tional complexes (Klotz 2000; Reid et al.
1999). Although these strategies are initially
effective at inducing cell death or cell cycle
arrest, recurrent tumors arise within a median
of 2–3 years, wherein AR activity has been
restored (Feldman and Feldman 2001). One
mechanism of AR re-activation is somatic
mutation of the AR (estimated to occur in
8–25% of recurrent tumors), where specific
mutations of the ligand binding domain ren-
der the receptor responsive to an expanded
host of ligands (Suzuki et al. 1993; Veldscholte
et al. 1990, 1992a, 1992b; Zhao et al. 2000).
Remarkably, it has been shown that one of the
most common tumor-derived mutant forms of
the AR, AR-T877A, is responsive to activation
by BPA (Wetherill et al. 2002, 2005).
Speciﬁcally, it was shown that at environmen-
tally relevant levels of BPA (1 nM), this agent
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BACKGROUND: Prostatic adenocarcinomas are dependent on androgen receptor (AR) activity for
growth and progression, and therapy for disseminated disease depends on ablation of AR activity.
Recurrent tumors ultimately arise wherein AR has been re-activated. One mechanism of AR restora-
tion is via somatic mutation, wherein cells containing mutant receptors become susceptible to activa-
tion by alternative ligands, including bisphenol A (BPA). In tumors with speciﬁc AR mutations,
BPA promotes therapeutic bypass, suggesting signiﬁcant negative impact to the clinical management
of prostate cancer.
OBJECTIVE: Our goal was to determine the mechanism of BPA action in cancer cells carrying BPA-
responsive AR mutants.
METHODS: The molecular signature of BPA activity in prostate cancer cells harboring mutant AR
was delineated via genetic microarray analysis. Speciﬁcity of BPA action was assessed by compari-
son with the molecular signature elicited by dihydrotestosterone (DHT).
RESULTS: BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells express-
ing the BPA-responsive mutant AR-T877A. BPA dramatically attenuated estrogen receptor beta
(ERβ) expression; this ﬁnding was speciﬁc to prostate tumor cells in which BPA induces cellular
proliferation.
CONCLUSIONS: BPA induces a distinct gene expression signature in prostate cancer cells expressing
somatic AR mutation, and a major molecular consequence of BPA action is down-regulation of
ERβ. Since ERβ functions to antagonize AR function and AR-dependent proliferation, these ﬁnd-
ings reveal a novel mechanism by which BPA likely regulates cellular proliferation. Future investi-
gation directed at dissecting the importance of ERβ in the proliferative response to BPA will
establish the contribution of this event to adverse effects associated with human exposure.
KEY WORDS: androgen receptor, endocrine disruptor, microarray, prostatic adenocarcinoma, xeno-
estrogen. Environ Health Perspect 115:1646–1653 (2007). doi:10.1289/ehp.10283 available via
http://dx.doi.org/ [Online 23 August 2007]is capable of binding and activating the mutant
receptor to induce endogenous expression of
PSA (prostate speciﬁc antigen, a known direct
AR target), which is used clinically to monitor
prostate cancer development and progression.
In cancer cells that express this mutant, low-
level BPA exposure induced androgen-inde-
pendent cellular proliferation, thereby
indicating that in the context of AR-T877A,
BPA exposure could potentially reduce thera-
peutic efﬁcacy. This concept was recently vali-
dated in vivo, wherein BPA accelerated tumor
growth after androgen ablation and signifi-
cantly reduced PSA doubling times (Wetherill
et al. 2006). Thus, there is signiﬁcant evidence
that BPA can bolster AR-T877A activity and
as a result potentially alter the course of thera-
peutic response in prostate cancer.
Given the potent effects of BPA on
mutant AR activation and prostate cancer
progression, it is imperative to determine the
molecular underpinning of BPA action.
There are differences in prostatic cellular
response to BPA compared with DHT,
including magnitude of proliferative response,
distinctions in ligand binding, and different
ligand-induced kinetics of AR recruitment to
gene regulatory regions (Wetherill et al. 2002,
2005). Moreover, it is known that differential
ligands dictate target gene specificity with
regard to the nuclear receptors. Although sub-
stantial in vitro analyses have revealed the
direct binding to and activation of mutant
ARs by BPA, it is also well documented that
BPA can activate ERα and ERβ, which are
expressed in several prostate cancer cell lines
[e.g., LNCaP (human prostatic adenocarci-
noma cell line)]. However, the BPA-induced
cellular proliferation is dependent on AR acti-
vation, as blocking of AR function (using the
speciﬁc AR antagonist, Casodex) reversed all
effects of BPA on tumor cell proliferation
(Wetherill et al. 2002). Therefore, it is
believed that the adverse proliferative effect of
BPA is directly through the AR. In our pre-
sent study, only the proliferation-inducing
dose of BPA (1 nM) was used for analysis.
We show by gene expression analyses that
low-level, physiologically relevant and prolif-
eration-inducing doses of BPA and DHT
elicit overlapping but distinct transcriptional
effects in prostate cancer cells expressing the
AR-T877A mutation. These data are consis-
tent with previous reports which demonstrate
that distinct AR ligands and modes of AR
activation alter the specificity of the target
genes modified (Davis et al. 2003; Matias
et al. 2000; Wilson et al. 1993), and suggest
that BPA likely uses mechanisms distinct
from DHT to promote cancer cell prolifera-
tion. Although these gene-expression differ-
ences are complex, interesting and suggestive
distinctions were observed. The analyses
revealed that BPA exposure in cells expressing
AR-T877A triggers a dramatic reduction in
expression of ERβ, a nuclear receptor sus-
pected to negatively regulate both AR activity
and prostate cancer cell proliferation. Modest
reductions in ERβ were observed after DHT
treatment. Strikingly, the ability of BPA to
modulate ERβ showed cell-type speciﬁcity, as
alteration in ERβ was observed only after
DHT (but not BPA) exposure in cells
expressing wild-type AR or the AR-H874Y
mutant. Together, these data identify ERβ as
a candidate effector of BPA action in prostate
cancer cells expressing the AR-T877A mutant
and demonstrate that BPA induces a unique
transcriptional signature in prostate cancer
cells that may be inﬂuenced by AR status.
Materials and Methods
Reagents. DHT and BPA were purchased
from Sigma-Aldrich Chemical Company (St.
Louis, MO). Both reagents were solubilized in
100% ethanol to 10-2M and stored at –20°C.
Cell culture. LNCaP cells were obtained
from American Type Culture Collection
(Rockville, MD) and were used between pas-
sages 28 and 40, maintained in Iscove’s modi-
fied Eagle’s medium (Cellgro; Mediatech,
Herndon, VA) containing 5% heat-inactivated
fetal bovine serum (FBS; Bioﬂuids, Rockville,
MD). The 22Rv1 cell line was the gift of
J. Jacobberger (Case Western Reserve
University, Cleveland, OH) and maintained in
Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% heat-inactivated FBS. LAPC4 cells
were the gift of C. Sawyers (University of
California, Los Angeles, CA) and were main-
tained in Iscove's modified Dulbecco's
medium (Cellgro; Mediatech) containing 10%
heat-inactivated FBS. Media for all cell types
were supplemented with 100 U/mL peni-
cillin–streptomycin and 2 mmole/L L-gluta-
mine (Mediatech). Cells were grown in a 5%
CO2-humidiﬁed incubator at 37°C. For cul-
ture in steroid-free conditions, cells were
seeded in phenol red-free media containing
charcoal-/dextran-treated FBS (CDT; Hyclone
Laboratories, Logan, UT).
Bromodeoxyuridine incorporation assay.
Cells were seeded in six-well dishes on poly-L-
lysine–coated coverslips at a density of
2.5 ×105 cells per well into CDT media
(allowing for depletion of AR ligands and AR
activity), then supplemented with either vehi-
cle (0.1% ethanol), 0.1 nM DHT, or 1 nM
BPA the following day. After 24 hr of treat-
ment, cells were labeled with cell proliferation-
labeling reagent (Cell Proliferation Labeling
reagent; Amersham, Buckinghamshire, UK)
according to manufacturer’s protocol, for
18 hr. Cells were then processed to detect
bromodeoxyuridine (BrdU) via indirect
immunofluorescence. Experiments were per-
formed with at least six independent biological
replicates, and at least 250 cells per experiment
were tallied per replicate for each condition.
Averages and standard deviation are shown.
Microarray hybridization. Vehicle con-
trol (0.1% EtOH), 0.1 nM DHT or 1 nM
BPA were added to LNCaP cells 24 hr after
seeding into CDT media. For each condition,
three independent samples were generated for
microarray analyses. After 24 hr of exposure
to reagents, total RNA was isolated via
TRIzol extraction for microarray analysis
from each independent biological replicate
(n = 3 per condition). The microarray experi-
ments were carried out essentially as described
in published reports and references therein
(Guo et al. 2004; Sartor et al. 2004). The
human 70-mer oligonucleotide library
version 2 (22,291 optimized oligos) (QIAGEN,
Alameda, CA) was suspended in 3× SSC
(sodium chloride–sodium citrate) at 30 µM
and printed at 22°C and 65% relative humidity
on aminosilane-coated slides (Cel Associates,
Inc. Pearland, TX) using a high-speed robotic
Omnigrid machine (GeneMachines, San
Carlos, CA) with Stealth SMP3 pins (Telechem,
Sunnyvale, CA).
Fluorescence-labeled cDNAs were synthe-
sized from total RNA using an indirect amino
allyl–labeling method via an oligo(dT)-
primed, reverse transcriptase reaction. Imaging
and data generation were carried out using a
GenePix 4000A and GenePix 4000B (Axon
Instruments, Union City, CA) and associated
software from Axon Instruments (Foster City,
CA). The microarray slides were scanned with
dual lasers with wavelength frequencies to
excite cyanine (Cy) 3 and Cy5 fluorescence
emittance. Images were captured in JPEG and
TIFF files, and DNA spots captured by the
adaptive circle segmentation method.
Information extraction for a given spot is based
on the median value for the signal pixels minus
the median value for the background pixels to
produce a gene set data file for all the DNA
spots. The Cy3 and Cy5 fluorescence signal
intensities were normalized.
Statistical analysis and functional testing
of microarrays. The data representing back-
ground subtracted spot intensities generated
by GenePix Pro software ,version 5.0 (Axon
Instruments) were analyzed to identify differ-
entially expressed genes. Data normalization
was performed in two steps for each microar-
ray separately (Guo et al. 2004; Sartor et al.
2004). First, background adjusted intensities
were log-transformed and the differences (M)
and averages (A) of log-transformed values
were calculated as M = log2(×1) – log2(×2)
and A = [log2(×1) + log2(×2)]/2, where ×1 and
×2 denote the Cy5 and Cy3 intensities,
respectively. Second, normalization was per-
formed by fitting the array-specific local
regression model of M as a function of A.
Normalized log-intensities for the two chan-
nels were then calculated by adding half the
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subtracting half the normalized ratio from A
for the Cy3 channel. The statistical analysis
was performed for each gene separately by ﬁt-
ting the following analysis of variance
(ANOVA) model (Dudiot and Fridlyand
2002). Resulting t-statistics from each contrast
were modified using an empirical Bayesian
moderated-T method (Smyth 2004). This
method uses variance estimates from all genes
to improve the variance estimates of each indi-
vidual gene. Estimates of fold change were cal-
culated, and genes with p-value < 0.05, fold
change > 2, and average spot intensity > 100
were considered for follow-up. Data analysis
was performed using the statistical software R
(http://www.bioconductor.org) and the
Bioconductor platform (http://www.r-project.
org). Average linkage hierarchial clustering was
performed using the uncentered correlation
similarity metric for the genes considered for
follow-up.
The gene list was analyzed to determine
which gene categories were enriched with dif-
ferentially expressed genes using EASE/
DAVID (Hosack et al. 2003), and the gene
sets tested were the three branches of the Gene
Ontology (GO) database (http://www.
geneontology.org). Fisher’s exact probability,
using the FDR (false discovery rate) multiple
testing adjustment, was calculated for each GO
term (Hosack et al. 2003).
Reverse transcriptase polymerase chain
reaction (PCR). RNA was isolated from cells
by TRIzol extraction, of which 5 µg was
used to generate cDNA with random hexam-
ers using the ThermoScript RT-PCR system
(Invitrogen, Carlsbad, CA). PCRs were
performed using the following primer sets:
PSA forward: CTTGTAGCCTCTCGTG
GCAC; PSA reverse: GACCTTCATAG
CATCCGT GAG; GAPDH forward:
CCACCCCATG GCAAATTCCATGCA;
GAPDH reverse: TCTAGACGGCAGGTC
AGGTCCACC; ERβ forward: CAGCAT
TCCCAGCAAT GTCAC; ERβ reverse:
GGTAAGGT GTTCTAGCGATCTTG;
WISP3 forward: AAGCAGGCTCTGG
GCAGCTA; WISP3 reverse: GACGTTGT
TGCAGTTCC; FKBP5 forward: GAGAAA
AGCCAGCATAAAGC; FKBP5 reverse:
TCTAGAACTTGCGTGGAAAG.
Amplifications were performed using Taq
DNA polymerase with the following condi-
tions: PSA and GAPDH 94°C 30 sec, 54°C
30 sec, and 72°C 30 sec; ERβ 94°C 30 sec,
56°C 1 min, and 73°C 1 min; WISP3 95°C
30 sec, 60°C 30 sec, and 68°C 30 sec;
FKBP5 95°C 30 sec, 56°C 1 min, and 73°C
1 min. Resulting products were resolved by
agarose gel electrophoresis.
Real-time PCR analysis of ERβ. Five
micrograms of total RNA were reverse-
transcribed into cDNA by Superscript III
reverse transcriptase (Invitrogen) according to
the manufacturer’s instructions. Real-time
PCR reactions containing Power SYBR Green
PCR Master Mix (Applied Biosystems),
250 ng cDNA template and 500 nM of ERβ
speciﬁc primers (ERβ forward: 5´-TGG CTA
ACC TCC TGA TGC TC-3´; ERβ reverse:
5´-TCC AGC AGC AGG TCA TAC AC-3´)
were prepared. Real-time PCR reactions in an
Applied Biosystems Prism 7900HT (Applied
Biosystems) were initiated by heating to 50°C
for 2 min and then to 95°C for 10 min. They
were followed by 40 cycles of denaturation
(95°C for 15 sec) and annealing/extension
(63°C for 30 sec). Dissociation curves of each
reaction were collected to evaluate the quality
of the end products. A standard curve for
ERβ was constructed by serial dilutions of the
expression vector prepared previously (Leung
et al. 2006). The copy number was deter-
mined according to the published formula
provided in the Applied Biosystems manual
(http://www.appliedbiosystems.com/).
Loading control was normalized by using
hGAPDH level using a published method
(Leung et al. 2006). Statistically analysis was
performed using one-way ANOVA with
Newman–Keuls test for multiple compar-
isons: *p < 0.05, **p < 0.01.
Immunoblotting. Cells were treated as
described for RNA isolation. However, for
protein analyses, total cells were pelleted and
whole cell lysates prepared using r adioim-
munoprecipitation buffer supplemented with
standard protease inhibitors and phenyl-
methylsulfonyl fluoride. Lysates were sub-
jected to brief sonication and clarified by
centrifugation. Equal protein concentrations
(~ 20 µg) were loaded and subjected to
sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Proteins were transferred to
Immobilon membrane (Millipore Corp.,
Bedford, MA) and immunoblotted for ERβ
or CDK4 (cyclin dependent kinase 4, loading
control) (antisera: H-150 and H-22, respec-
tively; Santa Cruz Biotechnology, Santa Cruz,
CA). Goat-anti rabbit (Alexa Fluor 680
A21076 1:10,000; Molecular Probes, Eugene,
OR) was used to visualize the antibody–
antigen complex.
Results
BPA initiates androgen-independent prostate
cancer cell proliferation in cells harboring the
AR-T877A mutation. To dissect the mecha-
nisms by which BPA modulated mutant AR
activity, conditions were used wherein BPA
exposure resulted in a signiﬁcant proliferative
advantage (Figure 1A). Briefly, AR-T877A–
expressing prostate cancer cells (LNCaP) were
initially cultured in hormone-depleted condi-
tions (CDT), to suppress cell cycle progression
and deplete endogenous AR of ligand. After
24 hr, cells were treated with DHT, BPA, or
vehicle (0.1% ethanol; EtOH) and pulsed with
5-bromo-2-deoxyuridine (BrdU) to measure
G1-S phase progression. As expected, androgen
depletion significantly attenuated cell cycle
progression compared with cells cultured in the
presence of physiological levels of DHT
(0.1 nM) (approximate 3-fold reduction in
BrdU incorporation, Figure 1B). Consistent
with previous reports for cells carrying BPA-
responsive AR mutants (Wetherill et al. 2002,
2005), BPA exposure also induced signiﬁcant
S-phase progression compared with vehicle
control (~ 2.5-fold induction over vehicle con-
trol). Similar trends were observed after
increasing time periods postligand stimulation
or when AR ligand stimulation was applied
after prolonged periods of hormone ablation
(data not shown). Previous studies showed that
BPA administration results in dose-dependent
proliferation (with concomitant increase in cell
number) of LNCaP cells in the absence of
androgen (Wetherill et al. 2002, 2005, 2006).
Hess-Wilson et al.
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Figure 1. BPA induces androgen-independent cellular proliferation in cells expressing AR-T877A.
(A) LNCaP cells were cultured under conditions of steroid hormone ablation (5% charcoal-/dextran-
treated serum, CDT) and subsequently stimulated with either DHT, BPA, or vehicle control [0.1% ethanol
(EtOH)]. (B) Cells cultured as in A were pulse labeled with BrdU for the last 16 hr of treatment, ﬁxed, and
BrdU incorporation was quantiﬁed by indirect immunoﬂuorescence. Percent BrdU positive cells is shown.
Error bars represent mean ± SD.
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Therefore, in this experimental paradigm,
DHT and BPA each elicit signiﬁcant effects on
cellular proliferation, and these strategies can
be used to dissect the molecular impact of BPA
on prostate cancer.
BPA elicits a distinct transcriptome in
prostate cancer cells. To determine the spe-
ciﬁc effects of BPA that underlie its pro-pro-
liferative capacity, parallel cultures were
examined for alterations in gene expression.
Briefly, cells were treated as described in
Figure 1 with either vehicle (EtOH), DHT,
or BPA before RNA isolation. A time course
was initially performed, where it was deter-
mined that BPA-induced PSA expression
peaks at 24 hr poststimulation compared with
approximately 16 hr after DHT stimulation
(data not shown). The delay in peak observa-
tion is consistent with previous observations
that AR nuclear translocation facilitated by
BPA is delayed compared with DHT-induced
AR translocation (Wetherill et al. 2002).
Therefore, this time point was chosen for sub-
sequent microarray analyses. RNA for each
condition (EtOH, DHT, and BPA) was iso-
lated from three independent experimental
cultures to determine the change in transcript
levels for each condition and when evaluated
in triplicate, genes passing the ANOVA crite-
ria were further analyzed to create a cluster
heat map. A heat map was generated using
the fold change estimates and averaged across
samples. As can be seen in Figure 2A, BPA
(column 1) and DHT (column 2) showed
some similar gene expression profiles with
comparable patterns of gene down-regulation
(green) and up-regulation (red) relative to the
vehicle control. However, column 3 provides
a visual mechanism to compare the proﬁle of
BPA with that of DHT and exemplifies the
differences in the genetic profile induced by
the two ligands. An important control and
point of reference, KLK3 (prostate-specific
antigen, PSA, UniGene ID# Hs.171995) was
up-regulated by both BPA and DHT but was
more robustly activated by DHT, as can be
seen by the green band in lane 3. Statistical
analyses revealed that a total of 283 genes
showed signiﬁcant alteration relative to vehicle
control (with p < 0.05, > 2-fold change in
gene expression and average intensity > 100 as
criteria for signiﬁcant changes). Of these, only
51 genes were common to both BPA and
DHT (38 up-regulated and 13 down-regu-
lated). However, 88 genes were uniquely regu-
lated by BPA treatment (51 up-regulated and
37 down-regulated), and 144 genes were
exclusive to DHT treatment (94 up-regulated
and 50 down-regulated) (Figure 2B). These
data suggest that although the proliferative
response to DHT or BPA is congruent, the
gene profiles after exposure are divergent
A B
C
BPA
88 genes
–51 up
–37 down
DHT
51 genes
–38 up
–13 down
144 genes
–94 up
–50 down
Criteria used were p < 0.05, fold change > 2, and average
intensity > 100.
Figure 2. BPA induces a unique transcriptome in prostate cancer cells expressing AR-T877A. Microarray
analyses were performed using triplicate biological replicates (n = 9) and statistical analyses performed
as described in “Materials and Methods.” (A) Heat map of the fold change estimates, averaged across
sample, showing all genes with a statistically signiﬁcant, > 2-fold alteration over vehicle control. Column 1
is statistically signiﬁcant changes in averaged gene expression in BPA-treated samples compared with
EtOH control; column 2 represents the statistically signiﬁcant changes in expression after DHT relative to
EtOH control. Column 3 is a comparative analysis and represents the genes that were statistically signiﬁ-
cant for BPA exposure compared with DHT treatments. Green bars indicate reduced expression, and red
bars indicate induced gene expression. The bar representing PSA (KLK3) is indicated. Microarray experi-
ment was performed on three independent experiments in triplicate. (B) VENN diagrams highlight the dis-
parity in DHT and BPA effects on gene regulation. C) Gene Ontology was performed as described in
“Materials and Methods.” Categories passing statistical signiﬁcance are shown. Gene annotations are
from Unigene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene).Hess-Wilson et al.
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between the canonical ligand DHT and the
environmental contaminant BPA.
Key target genes critical for DHT-medi-
ated AR-dependent proliferation are largely
unknown. Therefore, the expression changes
induced by mitogenic BPA or DHT were also
analyzed via GO to determine cellular path-
ways that may be altered by AR activation with
these disparate ligands (Figure 2C). The GO
terms that were affected are of signiﬁcant inter-
est to prostate development and organ home-
ostasis and function, as well as prostatic disease,
and include genes involved in the regulation of
cell proliferation, differentiation, organogene-
sis, and growth factor pathways. Among these
categories, several previously described direct or
suspected AR gene targets were identified in
both the DHT- and BPA-treated cohorts,
including prostate specific antigen (KLK3/
PSA), and FKBP5 (FK506 binding protein 5;
UniGene ID Hs.7557), a member of the
immunophilin protein family involved in pro-
tein trafﬁcking and folding. Notably, FKBP5
has been shown to be up-regulated in
xenograft models of androgen-independent
prostate cancer and induced by androgen expo-
sure in LNCaP cells (Magee et al. 2006). In
addition, several potentially key effectors of
prostate cancer cell proliferation were identi-
fied in the BPA-treated cohort, including
FIGF (c-fos–induced growth factor, also called
VEGF-D; UniGene ID Hs.11392), which has
been associated with advanced-stage metastatic
prostate cancer (Kaushal et al. 2005). The
WISP3 (WNT-1 inducible signaling pathway
protein 3, UniGene ID Hs.194678) gene,
whose protein product is a member of the
CCN (connective tissue growth factor,
cysteine-rich protein 61, and nephroblastoma
overexpressed gene) family, was also among
those induced by BPA. WISP3 is thought to
have important roles in carcinogenesis and
has identified functions in cell growth and
differentiation (Kleer et al. 2004). Other
potential effectors of BPA action included
SPBPBP (DNA-binding protein amplifying
expression of surfactant protein B; UniGene
ID Hs.3134), CRBP1, [cellular retinol-binding
protein type 1; UniGene ID Hs.208597, a
member of the retinoids, known to be involved
in cell growth, differentiation, and carcinogen-
esis, and which speciﬁcally has been found to
have altered methylation patterns in prostate
cancer (Jeronimo et al. 2004; Suzuki et al.
2006)], and IGF1 [insulin-like growth factor
(UniGene ID Hs.160562), thought to induce
cell survival/proliferation and a known activa-
tor of ligand-independent AR activity (Craft
et al. 1999; Culig et al. 1994)]. Last, the most
signiﬁcantly altered gene in the BPA data set
was ERβ (UniGene ID# Hs.443150), which
has been proposed to antagonize AR activity
and limit proliferation in prostatic epithelia
(Imamov et al. 2004a, 2004b; Weihua et al.
2002).
Given the potential importance of these
factors in facilitating BPA-induced cellular
proliferation, several of the pro-proliferative
genes and/or AR target genes were analyzed
for alteration in response to BPA treatment.
Using conditions identical to those used for
the microarray studies, cells were placed in an
environment of androgen ablation and subse-
quently stimulated with DHT or BPA for
24 hr. Initially, the AR target gene PSA was
analyzed. As expected, both DHT and BPA
increased PSA mRNA expression (Figure 3A,
left panel). Conversely, FKBP5 was increased
by DHT (8-fold over EtOH) but not signiﬁ-
cantly induced by BPA treatment (Figure 3A,
right panel). By contrast, BPA treatment
increased WISP3 (2-fold over EtOH control),
whereas DHT had no significant effect on
gene expression (Figure 3A, right panel). Last,
analyses of ERβ transcript levels were
explored by reverse transcriptase PCR, as
reduction of this mRNA was initiated by
both DHT and BPA (compare –2.6 fold
change by DHT with –4.8-fold change by
BPA in Figure 2C). Interestingly, both
microarray and reverse transcriptase PCR vali-
dation showed that BPA facilitated more sig-
niﬁcant down-regulation of ERβ than DHT
(Figure 3A, right panel, lane 3; 0.46-fold
expression compared with EtOH for BPA).
Real-time PCR was used to accurately
quantify the level of ERβ transcript down-reg-
ulation induced by DHT and BPA treatment
of LNCaP prostate cancer cells. As shown in
Figure 3B, cells cultured under conditions of
androgen ablation (EtOH vehicle treatment)
demonstrated approximately 20 relative copy
numbers of ERβ transcript. DHT treatment
reduced ERβ transcript to < 10 (a reduction of
50%, p < 0.05). Remarkably, BPA exposure
dramatically decreased ERβ transcript copy
number (~ 4, 80% reduction, p < 0.01;
Figure 3B). There was not a strong statistical
difference between the DHT- and BPA-medi-
ated reduction in ERβ (p > 0.05). These
results were further validated at the protein
level in parallel assays by immunoblotting for
ERβ. Therein, exposure of the cells to mito-
genic doses of BPA and DHT resulted in a
detectable decrease in ERβ protein (Figure 3C,
compare lanes 1, 3). CDK4 was used as the
loading control. Collectively, these data indi-
cate that although both BPA and DHT can
activate mutant AR and resultant cellular pro-
liferation in prostate cancer cells, each agent
induces a unique molecular signature, wherein
genetic proﬁles induced by mitogenic doses of
DHT or BPA showed both overlapping (e.g.,
PSA and ERβ) and divergent (e.g., FKBP5,
WISP3) responses.
BPA-mediated regulation of ERβ is cell-
type speciﬁc. The observation that BPA signiﬁ-
cantly reduced ERβ expression was striking, as
this receptor plays significant roles in both
Figure 3. Validation of selected targets reveals that BPA signiﬁcantly down-regulates ERβ expression in cells expressing the BPA-responsive AR-T877A mutant.
A) Validation of alterations in PSA expression was performed by RT-PCR. As expected, both DHT and BPA induced PSA expression in cells expressing AR-T877A
(left panel). In agreement with the microarray, it was also noted that BPA induces down-regulation of ERβ. By contrast, marked induction of WISP3 was also
noted, and no effect was observed with FKBP5 (right panel). Numbers correspond to the band intensity of each sample set to EtOH (EtOH = 1) and relative to the
GAPDH RNA control. B) The impact of BPA on ERβ was quantiﬁed by real-time PCR, and relative copy number was determined. Error bars represent mean ± SD;
n = 9; *p < 0.05, **p < 0.01. (C) Representative (n = 3) immunoblot of ERβ protein levels after BPA or DHT exposure. As shown, BPA exposure causes a marked
reduction in ERβ accumulation.
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(Adams et al. 2002; Leav et al. 2001).
Therefore, the speciﬁcity of BPA-induced ERβ
down-regulation was determined. The effect of
BPA treatment on ERβ transcript levels was
examined in two additional prostate cancer cell
lines, 22Rv1 and LAPC4. 22Rv1 cells are
androgen-independent prostate cancer cells
that express the AR-H874Y mutant. 22Rv1
cells were treated under identical conditions as
previously described, cells were switched to
steroid deprived media for 24 hr, then treat-
ments (EtOH vehicle control, DHT or BPA)
were added for 24 hr. As shown, cells treated
under conditions of hormone ablation demon-
strated a relative copy number of 7 (ERβ over
GAPDH control), as determined by quantita-
tive reverse transcriptase PCR. DHT reduced
the level of ERβ transcript copy by approxi-
mately 50% (p < 0.05); however, contrary to
observations in LNCaP cells, exposure to BPA
had no effect on ERβ transcript copy number
(Figure 4A).
The impact of BPA exposure on ERβ tran-
script was examined further in the LAPC4
prostate cancer cell line, which harbors wild-
type AR and is androgen dependent. Strikingly,
although the relative level of ERβ was lower in
LAPC4 cells, DHT treatment still resulted in
approximately a 40% reduction in ERβ gene
transcript (p < 0.05). However, similar to the
effect seen in 22Rv1 cells, BPA exposure did
not alter ERβ transcript levels (Figure 4B), as
evidenced by further reverse transcriptase PCR
(right panel) and quantified by quantitative
PCR (left panel). Combined, these data
demonstrate that the effect of BPA on reduc-
tion of ERβ gene expression is cell speciﬁc and
correlated with cells expressing the BPA-
responsive AR-T877A mutant.
Discussion
Somatic mutation of the AR is known to drive
recurrent tumor formation in a significant
percentage of patients undergoing hormone
therapy (Feldman and Feldman 2001;
Hirawat et al. 2003; Marcelli et al. 2000;
Navarro et al. 2002; Taplin et al. 2003;
Veldscholte et al. 1992a), and it has been
shown previously that selected AR mutants
become receptive to activation by the environ-
mental contaminant BPA. The clinical rami-
fications of BPA activating tumor-derived
mutant ARs and inducing androgen-indepen-
dent tumor cell proliferation may be substan-
tial, as BPA can reduce therapeutic efﬁcacy in
xenograft models (Wetherill et al. 2006).
While these data point toward the potential
for BPA to assist tumor cells in escaping ther-
apy, the molecular mechanisms of this process
were not well understood. In this study, the
molecular consequence of BPA action was
identified under conditions in which BPA
promotes androgen-independent proliferation.
Gene expression analyses revealed that in
AR-T877A–expressing cells, BPA elicited an
overlapping but distinct molecular signature
compared with that induced by exposure to
canonical AR ligand (DHT). Unexpectedly,
detailed examination of the most significant
targets demonstrated that BPA exposure
elicited dramatic reduction in expression of
ERβ, a nuclear receptor that is proposed to
antagonize AR activity and androgen-depen-
dent proliferation in prostatic epithelia (Leav
et al. 2001; Pravettoni et al. 2007; Weihua
et al. 2001). Comparative analyses revealed
that while DHT exposure also reduced ERβ,
this effect was marginal compared with the
BPA response. Last, the ability of BPA (but
not DHT) to attenuate ERβ function appears
to be speciﬁc to cell type and putatively recep-
tor speciﬁc, as BPA had no detectable effect on
ERβ expression in cells containing wild-type
AR or AR-H874Y. Notably, these also repre-
sent cell types in which BPA fails to induce
cellular proliferation. Together, these data
indicate that the ability of BPA to induce
androgen-independent cellular proliferation is
associated with AR-T877A expression and a
unique gene expression signature that involves
down-regulation of ERβ.
Combined with these observations, the
concept that BPA induces cell-specific tran-
scriptional proﬁles is emerging. For example,
transcriptional analysis of BPA exposure on
breast cancer cells (MCF-7) revealed that
BPA up-regulated a significant number of
genes involved in cell cycle progression and
purine and pyrimidine metabolism (Shioda
et al. 2006), reafﬁrming the proliferative bio-
logical action of this compound in estrogen-
dependent tissues. Interestingly, it has been
shown that BPA exposure increases ERβ in
some breast cancer lines (Cappelletti et al.
2003), suggesting that the direct activation of
ERs by BPA may facilitate the proliferative
response to these tissues. Additionally, it has
been shown that higher levels of BPA
uniquely regulate growth- and development-
related genes in breast cancer cells (Singleton
et al. 2006). From these data it is clear that in
estrogen-sensitive mammary tissues, BPA
exposure modulates pathways with important
biological outcomes (e.g., cell cycle progres-
sion), and that the effects of BPA augment
the known proliferative response to ER acti-
vation in this tissue type.
The ability of BPA to induce ERβ expres-
sion is in marked contrast to the observations
herein, where BPA signiﬁcantly reduced ERβ
mRNA and protein accumulation. Although
the biological functions of ERβ remain poorly
understood, in contrast to the proliferative
role of ERβ in mammary tissue, it is hypothe-
sized that functions of ERβ in the prostate
include antiproliferative action and regulation
of apoptosis (Lau et al. 2000; Leav et al. 2001;
Mak et al. 2006; Pravettoni et al. 2007).
Studies have demonstrated that loss of ERβ
signaling in prostatic epithelium results in
increased proliferation (Horvath et al. 2001;
McPherson et al. 2007; Pasquali et al. 2001)
and up-regulation of AR (Imamov et al.
2004a). Molecular analyses have shown that
ERβ can form a direct complex with AR and
abrogate its activity (Migliaccio et al. 2000).
Moreover, direct analysis of prostate disease
progression has shown that ERβ expression
declines as prostate cancer develops [although
expression is regained in lymph node and
bone metastasis (Horvath et al. 2001; Ji et al.
2005; Lai et al. 2004; Leav et al. 2001)]. In
mouse model systems, prostatic epithelial
hyperplasia can be attenuated by speciﬁc acti-
vation of ERβ (Imamov et al. 2004a, 2004b;
McPherson et al. 2002; Weihua et al. 2001,
2007). In the human population, the chemo-
prevention and protective nature of phyto-
estrogens in prostate cancer is hypothesized to
rely on the high binding afﬁnity and activating
potential of these estrogenic compounds for
ERβ (Kuiper et al. 1998; Leung et al. 2006).
Collectively, these data indicate that ERβ
BPA modulates ERβ expression in prostate cancer
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Figure 4. Specificity of BPA-mediated modulation of ERβ. ERβ expression was monitored using at least
two independent biological replicates for each condition and cell line, analyzed in triplicate and quantiﬁed
by real-time PCR in cells expressing AR-H874Y (22Rv1, A) or wild-type AR (LAPC4, B). Error bars represent
mean ± SD.
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GAPDHplays a significant role in regulating normal
prostate homeostasis (Horvath et al. 2001;
Leav et al. 2001; Weihua et al. 2001), and that
loss of ERβ plays a possible role in enhancing
the survival of prostate cancer cells (Kim et al.
2002; Lau et al. 2000; Neubauer et al. 2003).
The present observation that BPA initiates
ERβ down-regulation suggests that this may
be one mechanism by which BPA bolsters
overall AR activity, thereby promoting a pro-
liferative response. The observation that DHT
modestly altered ERβ levels was not expected,
as ERβ has not been well documented as a tar-
get (direct or indirect) of androgen action. Of
note, however, is that a signiﬁcant fraction of
published microarray studies using the
AR-dependent prostate cancer cell lines have
been performed using high doses of androgen
(≥ 10 nM) (Dehm and Tindall 2006), which
induce profound cell cycle arrest in prostate
cancer cells. Thus, it is possible that effects on
ERβ may be masked by such experimental
conditions. Furthermore, scrutiny of the liter-
ature demonstrated that down-regulation of
ERβ by DHT has been previously observed
but had not yet been validated (Arnold et al.
2005; Segawa et al. 2002). While the com-
plete molecular complexities of mitogenic sig-
naling in prostate cancer cells remain to be
elucidated, it would be interesting to continue
this line of experimentation with an analysis of
gene regulation as a function of time with the
various mitogenic ligands. However, together
these collective observations put forward the
intriguing hypothesis that the proliferative
effects of BPA may be at least partially due to
the manipulation of ERβ levels.
The ability of BPA to govern ERβ levels
was observed only in cells expressing the
AR-T877A mutant. This observation shows
critical speciﬁcity in BPA action; cells express-
ing wild-type AR or AR-T874Y, which are
nonresponsive to the mitogenic effects of BPA
(Wetherill et al. 2005), were impervious to the
BPA-facilitated changes in ERβ. Although
presently the possibility that cell-type speci-
ﬁcity is controlled by factors in addition to AR
mutation, it is intriguing to speculate about the
role of mutant AR in facilitating BPA-medi-
ated ERβ regulation. Previous work has shown
that BPA can activate AR-H874Y and elicit
transactivation of target genes in reporter assays
(Wetherill et al. 2005); however, because of the
ligand-independent nature of this cell line, AR
activation by either DHT or BPA does not
facilitate proliferation in AR-H874Y–depen-
dent (22Rv1) cells (Wetherill et al. 2005).
With regard to wild-type AR, BPA is not
known to bind to or activate this receptor at
the doses used, and LAPC4 cells (which
express wild-type AR) are not responsive to
androgen-independent cellular proliferation by
BPA exposure. By comparison, DHT-medi-
ated reduction of ERβ expression was relatively
equivalent in each of these lines, thus indicating
that the capacity to modulate ERβ remains
intact. Hence, the ability of BPA to alter ERβ
levels appears to correlate to the mitogenic
capacity of BPA. Future studies will be directed
at dissecting the mechanism by which AR lig-
ands alternately regulate ERβ and the contri-
bution of differential mutations of AR to this
process. In addition, given that BPA can bind
to ERβ directly, it will also be important to
determine whether the impact of BPA on ERβ
is direct or indirect. Recent work by Susiarjo
et al. (Susiarjo et al. 2007) have demonstrated
that the adverse effects of BPA on oocyte devel-
opment requires ERβ, further supporting the
notion that the salient mode of action for BPA
may be through alterations in ERβ function.
Remarkably, it still remains largely unknown
what controls ERβ expression in the prostate.
Although epigenetic regulation of ERβ in
prostate cancer has been reported (Zhu et al.
2004), knowledge of what cis-acting factors
directly interact with the ERβ promoter is very
limited; AP-2 was recently found to be a
promising transcription factor that regulates
ERβ gene expression (Zhang et al., in press).
In summary, the present study demon-
strates that BPA uses a cell-speciﬁc gene expres-
sion signature in prostate cancer cells
expressing a somatic mutation of AR, and that
a major molecular consequence of BPA action
is down-regulation of ERβ. These studies pro-
vide insight into a potentially novel mechanism
by which BPA can promote AR-T877A activ-
ity and androgen-independent cellular prolifer-
ation. Given the critical importance of
controlling AR activity for prostate cancer ther-
apy, the present study provides the foundation
for future investigations directed at dissecting
the role of BPA and ERβ in controlling
prostate cancer growth and/or progression.
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